William J. Steinbach

Federal Grant PI High Impact

Chair and Associate Dean

UAMS

Faculty Researcher

Pediatrics, College of Medicine

68 h-index 286 pubs 26,472 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group UAMS TRI Profile

OverviewAI-generated summary

William J. Steinbach leads a research program focused on the pathogenesis, diagnosis, and treatment of invasive fungal infections, particularly in immunosuppressed children. His work encompasses molecular, translational, and clinical research, with a long-standing NIH-funded multidisciplinary program supporting this patient population. Dr. Steinbach has held multiple Principal Investigator roles on R01 awards and has been instrumental in developing T32 training grants in molecular mycology and pediatric infectious diseases.

His clinical research has included multicenter prospective studies on biomarkers for invasive candidiasis and comparative effectiveness studies of antifungal agents in children. Dr. Steinbach also contributes to broader efforts addressing all infections in immunocompromised patients. His scholarly contributions are reflected in a high h-index of 68, over 286 publications, and more than 26,000 citations. He has also received federal funding for clinician research education and scientific training.

In addition to his research endeavors, Dr. Steinbach holds significant leadership positions. He serves as the Chair of Pediatrics and Associate Dean for Child Health at the University of Arkansas for Medical Sciences (UAMS), and as Pediatrician-in-Chief at Arkansas Children's. Previously, he was the Samuel L. Katz Distinguished Professor of Pediatrics and Vice Chair of Research at Duke University, where he directed the Children’s Clinical Research Unit and was Chief of Pediatric Infectious Diseases.

Metrics

h-index: 68
Publications: 286
Citations: 26,472

Selected Publications

Drugs for Parasitic Infections (2025)

2 citations DOI OpenAlex
New Approaches and a Call to Action (2025)

DOI OpenAlex
Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi (2024)

1 citation DOI OpenAlex
Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network (2024)

Journal of the Pediatric Infectious Diseases Society 3 citations DOI OpenAlex
Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi (2024)

DOI OpenAlex
Fecal Microbiota Transplantation: Information for the Pediatrician (2023)

PEDIATRICS 24 citations DOI OpenAlex
Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal (2023)

Nature 102 citations DOI OpenAlex
Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22-modified FK520 analog against C. neoformans (2023)

mBio 6 citations DOI OpenAlex
Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children: Secondary Analysis of Observed Practice From a Multicenter Cohort Study Conducted by the Pediatric Fungal Network (2023)

Journal of the Pediatric Infectious Diseases Society 6 citations DOI OpenAlex
Enhanced fungal specificity and in vivo therapeutic efficacy of a C-22 modified FK520 analog against C. neoformans (2023)

DOI OpenAlex
American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients (2023)

Transplantation and Cellular Therapy 4 citations DOI OpenAlex
Calcineurin Inhibitor CN585 Exhibits Off-Target Effects in the Human Fungal Pathogen Aspergillus fumigatus (2022)

1 citation DOI OpenAlex
Prospective Evaluation of the Fungitell® (1→3) <scp>Beta‐D‐Glucan</scp> Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group (2022)

Pediatric Transplantation 10 citations DOI OpenAlex